Our Innovation Journey
At Glenmark, we explore the unparalleled possibilities of science and innovation to create breakthrough therapies for the global patient population. Our sustained investment in research and development helps us identify and advance promising treatments that benefit millions of patients globally. We are home to some of the best global scientific talent that continuously challenges treatment paradigms and builds on the success of established franchises. At present, our portfolio of differentiated medicines in respiratory, dermatology and oncology is acclaimed as breakthrough solutions for a wide range of diseases.
Our innovation footprint
2 molecules
in Glenmark Pharmaceuticals’ speciality/innovative pipeline
5 molecules
in Ichnos’ innovative biologics pipeline
1400+
inventions till date
1300
patents granted for innovations in
NCE, Formulations, API and Design
~ USD 300 Mn
worth of out-licensing deals signed
Reference : Glenmark Annual Report 2022 – 2023
Enriching lives globally through our products
First company to launch oral drug Favipiravir (FabiFlu®), in India for the treatment of mild to moderate COVID-19 cases which has helped in the treatment of > 5 Mn patients till date.
Ryaltris™ (olopatadine hydrochloride and mometasone furoate monohydrate), an anti-allergy nasal spray is being marketed globally as a treatment option for seasonal and perennial allergic rhinitis in adults and children over 12 years of age.
First company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India under two brand names Remo MV and Remozen MV.
Out-licensing deals over the years
Glenmark’s 100% subsidiary Ichnos Sciences and Almirall enter into a licensing agreement for first-in-class iL-1RAP antagonist monoclonal antibody ISB 880. Under the agreement, Almirall is granted global rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
Glenmark out-licenses mPGES-1 inhibitor to Forest Labs for USD 15 Mn (upfront payment)
Glenmark out-licenses GBR 500 to Sanofi-Aventis for USD 50 Mn (upfront payment) and USD 5 Mn (milestone payment) in 2014
Glenmark out-licenses GRC 15300, a first-in-class TRPV3 antagonist to Sanofi-Aventis for USD 25 Mn (upfront payment)
Glenmark out-licenses TRPV1 antagonist molecules to Eli Lilly for USD 45 Mn (upfront fee)
Glenmark out-licenses Melogliptin to Merck KGaA for USD 31 Mn (total payment)
Glenmark out-licenses Oglemilast to Teijin Pharma, Japan for USD 6 Mn (upfront payment)
Glenmark out-licenses GRC 3886 to Forest Laboratories for USD 35 Mn (upfront and milestone payments)
In the news
- Ichnos Sciences looks forward for partnership for another auto-immune asset ISB 830 following licensing agreement with Almirall ISB 880 Monoclonal Antibody – Link (Financial Express)
- Glenmark's US arm signs licensing deal – Link (Times of India)
- Ichnos sciences presents preclinical data on novel isb 1442 in relapsed/refractory multiple myeloma at the ash 2021 annual meeting – Link (PRNewswire)
- Glenmark launches unique fixed dose combination drug for diabetes – Link (ETHealthworld)
- Glenmark launches dry powder inhaler Tavulus in Spain – Link (BioSpectrum India)
- Glenmark to market Ryaltris in 13 countries across EU and UK – Link (Business Standard)
- Glenmark Pharmaceuticals sees potential of NONS to prevent Covid-19 – Link (Business Standard)
- Glenmark Pharma receives approval for clindamycin phosphate foam - Link (Business Standard)
- Glenmark gets CDSCO panel okay for phase 3 trial of nitric oxide nasal spray – Link (Medical Dialogues)
- Glenmark Pharma gets approval for Nintedanib Capsules – Link (Business Standard)
- Glenmark Pharma gets approval for Arformoterol Tartrate Inhalation Solution – Link (Business Standard)
- Glenmark Pharma gets approval for Theophylline Tablets – Link (Business Standard)
- Glenmark Pharmaceuticals launches Rufinamide Tablets – Link (Business Standard)
- Glenmark gets US FDA nod for Icatibant injection, 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe – Link (Express Pharma)
- Glenmark Pharma launches nasal spray Ryaltris in India – Link (Economic Times)
- Glenmark Pharma to launch its nasal spray Ryaltris in European Union – Link (Moneycontrol)
- Glenmark receives USFDA approval for Chlorpromazine Hydrochloride Tablets – Link (Business Standard)
- Glenmark receives 'India Pharma Innovation of the Year' Award from the govt. of India – Link (Business Standard)
- Glenmark Pharma's Ryaltris gets approval in Russia – Link (Business Standard)
- Glenmark launches SUTIB at an affordable MRP in India – Link (Business Standard)
- Glenmark gets USFDA nod for acne treatment drug – Link (Economic Times)
- Glenmark Pharma gets USFDA nod for amphetamine sulfate tablets – Link (Business Standard)
- Glenmark launches Remo V and Remozen V for treatment of Type 2 diabetes – Link (Business Standard)
- Glenmark receives USFDA approval for Dabigatran Etexilate Capsules – Link (Business Standard)
- Glenmark receives final USFDA approval for Tacrolimus Capsules – Link (Business Standard)
- Glenmark launches stronger FabiFlu. Covid patients now need half number of tablets – Link (Mint)
- FabiFlu: Glenmark launches Covid drug at Rs 103 per tablet – Link (Financial Express)
News
- March 2023
Scrip Pharma Intelligence Informa
27 March 2023
Cnbctv18
16 March 2023
Health Economic Times
07 February 2023
Health Economic Times
01 February 2023
Economic Times
22 December 2022
Financial Express
15 December 2021
Financial Express
24 March 2022
PRNewswire
14 December 2021
Business Standard
30 September 2021